Results 161 to 170 of about 31,387 (227)

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1250-1270, March 2026.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma. [PDF]

Cancer Immunol Immunother
Váradi M, Horváth O, Soós E, Csizmarik A, Németh B, Győrffy B, Kenessey I, Reis H, Koll F, Oláh C, Hadaschik B, Krafft U, Grünwald V, Mairinger F, Wessolly M, Hoffmann MJ, Grunewald CM, Niegisch G, Cotarelo CL, Maráz A, Kuthi L, Szász AM, Herold Z, Posta M, Bátai B, Nyirády P, Szarvas T.   +26 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Longitudinal Impact of Urinary Diversion on Health‐Related Quality of Life After Radical Cystectomy: A Multicenter Study in Japan

Cancer Science, Volume 117, Issue 3, Page 739-748, March 2026.
This multicenter prospective study examined the impact of urinary diversion on HRQOL among bladder cancer patients who underwent radical cystectomy. Evaluation using the BCI clarified changes in HRQOL related to urinary, bowel, and sexual domains before surgery and at 3, 6, and 12 months postoperatively.
Shuhei Yamada, Miho Sato, Takahiro Osawa, Toru Harabayashi, Jun Miki, Takashi Kobayashi, Katsuyoshi Hashine, Atsunari Kawashima, Takashi Matsumoto, Takanori Mochizuki, Rikiya Taoka, Fumihiko Urabe, Shuichi Tatarano, Atsuro Sawada, Takahiro Kojima, Atsushi Takahashi, Akira Yokomizo, Shigetaka Suekane, Kohei Hashimoto, Yasuhiro Hashimoto, Junji Yatsuda, Ken Morita, Keita Kobayashi, Yohei Satake, Ataru Sazawa, Yoshiyuki Matsui, Yoichi M. Ito, Sayaka Shimizu, Shunichi Fukuhara, Hiroyuki Nishiyama, Hiroshi Kitamura, Nobuo Shinohara, on behalf of the Japanese Urological Oncology Group   +32 more
wiley   +1 more source

Is There a Role for Surgery in the Treatment of Metastatic Urothelial Carcinoma? [PDF]

J Clin Med
Bhalla S, Pfail J, Ghodoussipour S.
europepmc   +1 more source

Decoding Senescence‐Driven Heterogeneity in Early‐Onset Colorectal Cancer for Prognostic and Therapeutic Stratification

Cancer Science, Volume 117, Issue 3, Page 818-835, March 2026.
We uncovered pronounced and heterogeneous tumor senescence in EOCRC, independent of age. By integrating multi‐omics and single‐cell analyses, we developed EO‐Senscore, a prognostic tool that stratifies patients by immune phenotype and therapy response, enabling precision treatment using immunotherapy or senolytic agents. ABSTRACT Early‐onset colorectal
Du Cai, Mingru Mai, Rende Huang, Haoning Qi, Xingzhi Feng, Qianling Gao, Yinmeng Zhang, Chenghang Li, Xiaojian Wu, Yize Mao, Zihuan Yang, Feng Gao   +11 more
wiley   +1 more source

Local Therapy of the Primary Tumor: An Option for Metastatic Urothelial Carcinoma in the Era of Novel Combination Therapies? [PDF]

Eur Urol Open Sci
Pichler R, Subiela JD, Mayr R, Moschini M, Li R, Pradére B.   +5 more
europepmc   +1 more source

Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non‐Muscle‐Invasive Bladder Cancer

Cancer Science, Volume 117, Issue 3, Page 787-796, March 2026.
Urinary tumor DNA (utDNA) represents a powerful noninvasive biomarker to refine the need for repeat TURBT in high‐risk NMIBC. In our cohort of 161 patients, utDNA testing achieved superior accuracy to cytology, strongly predicted residual disease and recurrence, and could safely reduce unnecessary repeat resections by up to one‐third.
Zihan Xue, Yunkai Qie, Chong Shen, Zhouliang Wu, Houyuan Chen, Yuda Lin, Rongjiang Li, Shiwang Huang, Hailong Hu   +8 more
wiley   +1 more source

Safety of Enfortumab Vedotin Plus Pembrolizumab in Hemodialysis Patients With Metastatic Urothelial Carcinoma: Case Report. [PDF]

Cancer Diagn Progn
Mizuno T, Kobari Y, Ito H, Yoshino M, Nakamura K, Ikeda T, Nakayama T, Minoda R, Wada A, Fukuda H, Yoshida K, Iizuka J, Ishida H, Takagi T.   +13 more
europepmc   +1 more source

Baseline geriatric 8 (G8) screening tool predicts overall survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors. [PDF]

Oncologist
Rhee CH, Goyal S, Liu Y, Martini DJ, Shabto JM, Nazha B, Kucuk O, Carthon BC, Bilen MA, Brown JT.   +9 more
europepmc   +1 more source